Cambrios lands $14.5M for electronic display components
Cambrios, maker of conductive films used in electronic displays and monitors, has brought in $14.5 million in a fourth round of venture capital. Based in Sunnyvale, Calif., the company is backed by ARCH Venture Partners, Alexandria Real Estate Equities, Alloy Ventures, Altitude Life Science Ventures, Avalon Ventures, Harris & Harris Group, Headland Ventures, In-Q-Tel, Kidron, Lux Capital, Mitsubishi UFJ Capital, Oxford Bioscience Partners, Presidio Ventures, Sumitomo, Chisso and Nissha Printing.
Pathway Medical lands generous $40M to treat arterial disease
Pathway Medical Technologies, maker of a non-invasive catheter capable of removing all kinds of artery blockages and build-up, says it just scored $40 million in a fourth round of funding — a pretty high figure for a life science device manufacturer these days. Only about 11 percent of these companies have raised more than $25 million in the last two years. The Kirkland, Wash. company says it will use the money to grow its sales… Continue Reading
Concentric Medical closes $15M to ease stroke symptoms
Concentric Medical, developer of minimally invasive devices used to remove blood clots in ischemic stroke patients, took $15 million in new venture backing to expand its product portfolio and run more clinical trials. The Mountain View, Calif. company says it ended 2008 on a strong financial note that helped attract investors despite the tight economy. This is an uptick from February, when it withdrew its plans for a $69 million initial public offering.
Concentric Medical’s devices… Continue Reading
Luca shovels in $76M for coal-to-gas technology
Coal is no longer the dirty word it once was. And there’s no better indication than the $75.9 million recently pulled in by Luca Technologies, a company that engineers microbes to produce methane gas from coal. This brand of innovation could be good news all around as the incoming presidential administration emphasizes clean-burning energy despite cheap surpluses in the U.S. coal supply.
The round, which will be used to acquire new coal beds in Wyoming’s Powder… Continue Reading
Migraine sufferers look elsewhere as Cierra buckles
The headache is over for medical device maker Cierra. Actually it’s all over. The Redwood City, Calif.-based company is out of business after failing to draft enough participants into a clinical trial of a catheter-based technology purported to reduce migraines, VentureWire reported. It takes $29 million in venture capital down with it from investors Delphi Ventures, Frazier Healthcare Ventures, Morgenthaler Ventures and Split Rock Partners.
Believing that migraines could be made less frequent by sealing a… Continue Reading
Life-science briefing: Monday, March 10, 2008
TODAY’S HEADLINES:
BrainCells raises $30M for neuroregeneration drugs (release)
EKR Therapeutics takes in $50M plus $95M in debt for pain, heart drugs (release)
Wright Medical acquires Berkeley’s Inbone Tech for $24M (release)
Argolyn Bioscience names Nixon Ellis as CEO (release)
BrainCells raises $30M for neuroregeneration drugs – San Diego’s BrainCells, a startup focused on drugs intended to stimulate the growth of new neurons, raised $30 million in a second funding round. Investors included MedImmune Ventures, Bay City Capital, Oxford Bioscience Partners,… Continue Reading
Life sciences briefing: Monday, Jan. 14, 2008
TODAY’S HEADLINES:
Autonomic Technologies raises $3M for neurostimulators (PE Hub)
Canopy Financial raises $15M for outsourced healthcare management (release)
Cancer-drug developer AmpliMed draws $5M (PE Hub)
Caprotec Bioanalytics receives €6M for protein-analysis tech (release)
ProtAffin draws additional €1.4M for anti-inflammatory drugs (release)
Toxicology-services firm Bridge Labs takes in $18M (release)
Dental-compound maker NovaMin takes in $2.2M (TechJournal South)
Aushon Bio takes in $4M for microarrays (PE Hub)
Treatment Online receives $750K for Web behavioral healthcare (PDF release)
IPO the Hospitalist aims to raise $60M with… Continue Reading
Life sciences briefing: Wednesday, Oct. 31, 2007
Featured companies: AerovectRx, Dicerna Pharmaceuticals, Harmony Information Systems, Intelligent Hospital Systems, Merrion Pharmaceuticals, Syntaxin, SymBio Pharmaceuticals
UPDATED: Expanded items on Harmony Info, SymBio Pharma and Merrion Pharma, added Dicerna item.
UPDATE REDUX: Added Syntaxin item.
U.K. biotech Syntaxin raises £16M for pain and nervous-system drugs — Syntaxin, a U.K. biotech focused on drugs that affect cell secretion, raised £16 million ($33.2 million) in a second funding round. The company’s release is here.
Investors in the round included SR One, the venture capital… Continue Reading
Life sciences briefing: Thursday, Oct. 25, 2007
Featured companies: BioVex, Cavadis, Innovention, Paratek Pharmaceuticals, Phase Bioscience, Reliant Pharmaceuticals, Xencor
UPDATED: Expanded Paratek and Xencor items.
Paratek Pharma raises $40M for new antibiotics — Boston’s Paratek Pharmaceuticals, a biotech working on new antibiotics to treat drug-resistant bacterial infections, raised a first tranche of a $40 million eighth round of funding. The company’s release is here, VentureWire (subscription required) has more details here.
Investors in this funding included Aisling Capital, D.E. Shaw, Boston Life Science Venture Corporation, Nomura Phase4… Continue Reading
LUCA raises $20M more to convert dirty coal into natural gas
LUCA Technologies, a Golden, Colo. company developing technology to convert dirty coal into natural gas, has raised $20 million more in financing.
The company joins a host of others working on similar conversion technologies. LUCA’s technology is different in that it works underground, seeding changes to micro-organisms within hydrocarbon deposits like coal, which stimulates conversion into methane.
Silicon Valley venture firm Kleiner Perkins and Boston’s Oxford Bioscience Partners led the investment, according to VentureWire (subscription required). The… Continue Reading
Life sciences briefing: Monday, Aug. 6, 2007
(UPDATED at 5:05 p.m. PDT; see below.)
(As part of my ongoing effort to strike the right balance between keeping up with venture-business news and writing more analysis, I’m inaugurating a daily briefing that will collect deal-related news items from the life sciences in one place. I’ll continue updating this post throughout the day as the news dictates. Comments on this or any other feature of this blog are always welcome; sound off below. For more on… Continue Reading
Amgen snaps up another biotech startup, Alantos Pharma, for $300M
Amgen suddenly has a voracious appetite for startups. In its second deal this week, the biotech giant acquired Cambridge, Mass., biotech Alantos Pharmaceuticals for $300 million in cash. (The release is here.)
Founded in Heidelberg, Germany in 1999, Alantos changed its name from Therascope in 2003 and moved to Cambridge in 2004. The company develops traditional “small molecule” drugs — that is, therapies that can be delivered as pills rather than shots — for a… Continue Reading
Intechra, electronics recycler, gets $30M
Intechra Holdings, a Jackson, Miss. company that recycles electronics, said it has raised $30 million in a third round of financing, making it just the latest in a hot trend of green investing.
See the company’s statement here.
The funding was led by Richland Ventures, of Nashville, Oxford Bioscience Partners, of Boston, and First Avenue Partners, of Nashville, the company said. Other investors included existing backers Chrysalis Ventures, Sewanee Partners and SJF Ventures. The company has raised… Continue Reading
Cancer-drug maker Aveo raises $53M
Aveo Pharmaceuticals, a Cambridge, Mass. cancer-drug company, raised $53 million in a fourth round of funding from a coalition of mostly blue-chip life-science investors.
New investors included Biogen Idec, Bessemer Venture Partners, Merlin BioMed Group, Mitsubishi UFJ Financial Group and Vatera Holdings, an investment vehicle owned by Kos Pharmaceuticals founder Michael Jaharis. Schering-Plough also provided a $10 million equity investment as part of a collaboration agreement.
The round also included new funding from existing investors Highland… Continue Reading